Veru announces selection of modified release of enobosarm for PK study

Veru (VERU) announced selection of a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management, following confirmation of pharmacokinetic, PK, endpoints in a clinical study. The single dose, open label pilot study evaluated the plasma concentration versus time profile of a proprietary, patentable modified release formulation of enobosarm 3mg. The new formulation demonstrated the intended distinct target product release profile, which includes a reduction in maximum plasma concentration, a delayed time to maximum plasma concentration, a distinct secondary peak plasma concentration, and similar extent of absorption compared to historical values for enobosarm immediate release capsules.